BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Rhea-AI Summary
BioMark Diagnostics (OTCQB: BMKDF) and research partners were awarded the ADRIQ Innovation Award on November 27, 2025 for a multimodal lung cancer screening project that combines a metabolomic blood test, clinical data and AI to estimate lung cancer probability. The project is valued at $4.42 million and was funded via the Government of Quebec through CQDM with support from AstraZeneca Canada, Pfizer Canada and IUCPQ-UL. The work created a biobank consolidating clinical data and samples from over 3,000 participants tied to Quebec’s lung screening program. BioMark says it is seeking accreditation for its Quebec facilities to support provincial integration and future international scaling.
Positive
- $4.42M project funding from Quebec/CQDM
- Biobank of over 3,000 participant samples and clinical records
- Strategic collaboration with AstraZeneca Canada and Pfizer Canada
- ADRIQ Innovation Award recognition (Nov 27, 2025) validating approach
Negative
- Operational rollout dependent on accreditation of Quebec facilities
- Initial deployment targeted to Quebec first, limiting near-term geography
News Market Reaction
On the day this news was published, BMKDF gained 46.50%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BMKDF gained 4.61% while key peers were mixed: ANGLE PLC’s listings rose 14.68% (ANPCF) and 35.24% (ANPCY), IZOZF was up 1.91%, and IMMVF/BIOQ were flat. With sector momentum flagged as stock-specific, the move appears more tied to BioMark’s own news than a broad diagnostics rally.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Innovation award | Positive | +46.5% | ADRIQ Innovation Award for multimodal lung cancer screening project in Quebec. |
| Nov 12 | Strategic alignment | Positive | -6.8% | Support for 2026–2035 Pan-Canadian Lung Cancer Action Plan and partnership outreach. |
| Sep 29 | Patent grants | Positive | +0.0% | Patents secured in China and Japan plus >90% sensitivity data for early detection. |
| Aug 05 | Lab expansion | Positive | +3.3% | Quebec lab capacity doubled via equipment lease to support commercial launch. |
| Jul 30 | FY results & plans | Positive | -2.4% | Fiscal 2025 achievements, capital raises, and ambitious 2025–2026 growth milestones. |
Positive operational and strategic updates often saw supportive or strong gains, but there are notable instances where upbeat news coincided with short-term pullbacks.
Over the past months, BioMark reported several milestones, including fiscal 2025 achievements with CAD $4.26 million raised and a planned 6,000-patient trial, expansion of Quebec lab capacity, and patents in China and Japan with >90% sensitivity for early lung cancer detection. The company later aligned with the 2026–2035 Pan-Canadian Lung Cancer Action Plan. Today’s ADRIQ Innovation Award for a $4.42 million multimodal lung cancer screening project builds directly on this commercialization and partnership trajectory, reinforcing earlier strategic themes.
Market Pulse Summary
The stock surged +46.5% in the session following this news. A strong positive reaction aligns with BioMark’s pattern of gains on clear commercialization and validation milestones, as seen after lab expansion and patent wins. This award-backed, $4.42 million project and biobank of over 3,000 participants reinforced confidence in its platform. However, past pullbacks after positive strategic news suggest enthusiasm has sometimes faded, so investors have historically had to weigh execution timelines and previous capital-raising needs against near-term optimism.
Key Terms
liquid biopsy medical
metabolomic blood test medical
biomarkers medical
artificial intelligence technical
biobank medical
AI-generated analysis. Not financial advice.
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ Innovation Awards Gala. The award ceremony, held on November 27, 2025, celebrated the collaboration between Quebec-based BioMark Diagnostic Solutions, Astra Zeneca Canada, Pfizer Canada and the IUCPQ-UL research team (Dr. Philippe Joubert and Dr. Yohan Bossé).
The recognition highlights the successful development of an innovative multimodal approach designed to predict lung cancer risk, enabling simpler, earlier, and less invasive screening. At the heart of this initiative is BioMark's metabolomic blood test, which combines the analysis of blood biomarkers with clinical data using artificial intelligence to calculate the probability of lung cancer presence. The award highlights the power of combining academic excellence with industrial innovation to bring life-saving diagnostic tools to market.
Revolutionizing Lung Cancer Screening in Quebec and Beyond
This groundbreaking project, valued at
"Winning the ADRIQ Innovation Award is a powerful de-risking event for BioMark, validating our ability to successfully translate cutting-edge science into clinically relevant, commercial tools through strategic public-private partnerships," said Rashid Ahmed Bux, President & CEO of BioMark Diagnostics Inc. "The success in Quebec provides a clear operational blueprint for our international scaling. We are leveraging Canadian innovation, expertise, and infrastructure to target a truly global market opportunity."
Dr. Jean-François Haince, General Manager and CSO, stated, "This recognition underscores the critical role that collaborative innovation plays in transforming healthcare. By structuring and making this unique patient cohort available to private research partners, IUCPQ-UL researchers are fostering scientific discovery in Quebec and establishing a powerful, validated resource that will enable the next generation of diagnostics. Quebec, a pioneer in lung screening, will be the first province to benefit from this innovation. We look forward to bringing it to market and transforming access to precision diagnostics for patients."
The company has strengthened its operational capabilities and is seeking accreditation for its Quebec facilities to ensure analyses meet international standards, paving the way for provincial screening program integration and nationwide rollout.
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved, or disapproved of the content of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276283
FAQ
What did BioMark (BMKDF) win on November 27, 2025?
How much funding supported BioMark's lung screening project (BMKDF)?
How large is the biobank created by BioMark's project (BMKDF)?
Which partners supported BioMark's lung cancer screening project (BMKDF)?
What must BioMark (BMKDF) complete before provincial screening integration?
